Skip to main content

Advertisement

SpringerLink
Log in

Pancreatic neuroendocrine tumors

  • REVIEW ARTICLE
  • Published:
Indian Journal of Gastroenterology Aims and scope Submit manuscript

Abstract

Pancreatic neuroendocrine tumors (pancreatic NETs) are rare, low- to intermediate-grade neoplasms thought to arise from the pancreatic islets. Recent advances in pathology and our understanding of the biological behavior of this group of tumors has resulted in changes in their nomenclature and how we treat them. This review puts into perspective our current understanding of pancreatic NETs in terms of their incidence, pathology, and management.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Yao J, Rindi G, Evans D. Pancreatic neuroendocrine tumors. In: DeVita V Jr, Lawrence T, Rosenberg S, editors. DeVita, Hellman, and Rosenberg's cancer: principles and practice of oncology. Philadelphia: Lippincott Williams & Wilkins; 2011. p. 1489–502.

    Google Scholar 

  2. Davies K, Conlon KC. Neuroendocrine tumors of the pancreas. Curr Gastroenterol Rep. 2009;11:119–27.

    Article  PubMed  Google Scholar 

  3. Klöppel G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann N Y Acad Sci. 2004;1014:13–27.

    Article  PubMed  Google Scholar 

  4. Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine tumors. Lancet Oncol. 2008;9:61–72.

    Article  PubMed  CAS  Google Scholar 

  5. Halfdanarson TR, Rabe KG, Rubin J, Petersen GM. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol. 2008;19:1727–33.

    Article  PubMed  CAS  Google Scholar 

  6. Lam KY, Lo CY. Pancreatic endocrine tumour: a 22-year clinico-pathological experience with morphological, immunohistochemical observation and a review of the literature. Eur J Surg Oncol. 1997;23:36–42.

    Article  PubMed  CAS  Google Scholar 

  7. Hauso O, Gustafsson BI, Kidd M, et al. Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer. 2008;113:2655–64.

    Article  PubMed  Google Scholar 

  8. Amarapurkar DN, Juneja MP, Patel ND, Amarapurkar AD, Amarapurkar PD. A retrospective clinico-pathological analysis of neuroendocrine tumors of the gastrointestinal tract. Trop Gastroenterol. 2010;31:101–4.

    PubMed  CAS  Google Scholar 

  9. Bhatia P, Srinivasan R, Rajwanshi A, et al. 5-year review and reappraisal of ultrasound-guided percutaneous transabdominal fine needle aspiration of pancreatic lesions. Acta Cytol. 2008;52:523–9.

    Article  PubMed  Google Scholar 

  10. Oberg K, Akerström G, Rindi G, Jelic S, ESMO Guidelines Working Group. Neuroendocrine gastroenteropancreatic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21 Suppl 5:v223–7.

    Article  PubMed  Google Scholar 

  11. Klöppel G. Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer. 2011;18 Suppl 1:S1–S16.

    Article  PubMed  Google Scholar 

  12. Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas. 2010;39:707–12.

    Article  PubMed  Google Scholar 

  13. Rindi G, Arnold R, Bosman F, et al. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: Bosman F, Carneiro F, Hruban R, Theise N (eds.) WHO Classification of Tumors of the Digestive System. Lyon: IARC Press; 2010. p. 13–4.

    Google Scholar 

  14. Sobin L, Gospodarowicz M, Wittekind C. UICC: TNM classification of malignant tumors. 7th ed. Oxford: Wiley-Blackwell; 2009.

    Google Scholar 

  15. Rindi G, Kloppel G, Alhman H, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2006;449:395–401.

    Article  PubMed  CAS  Google Scholar 

  16. Ekeblad S, Skogseid B, Dunder K, Oberg K, Eriksson B. Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clin Cancer Res. 2008;14:7798–803.

    Article  PubMed  CAS  Google Scholar 

  17. Strosberg JR, Cheema A, Weber J, Han G, Coppola D, Kvols LK. Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors. J Clin Oncol. 2011;29:3044–9.

    Article  PubMed  Google Scholar 

  18. Scarpa A, Mantovani W, Capelli P, et al. Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Mod Pathol. 2010;23:824–33.

    Article  PubMed  CAS  Google Scholar 

  19. Kloppel G, Rindi G, Perren A, Komminoth P, Klimstra DS. The ENETS and AJCC/UICC TNM classifications of the neuroendocrine tumors of the gastrointestinal tract and the pancreas: a statement. Virchows Arch. 2010;456:595–7.

    Article  PubMed  Google Scholar 

  20. Mallinson CN, Bloom SR, Warin AP, Salmon PR, Cox B. A glucagonoma syndrome. Lancet. 1974;2:1–5.

    Article  PubMed  CAS  Google Scholar 

  21. Remes-Troche JM, Garcia-de-Acevedo B, Zuniga-Varga J, Avila-Funes A, Orozco-Topete R. Necrolytic migratory erythema: a cutaneous clue to glucagonoma syndrome. J Eur Acad Dermatol Venereol. 2004;18:591–5.

    Article  PubMed  CAS  Google Scholar 

  22. van Beek AP, de Haas ER, van Vloten WA, Lips CJ, Roijers JF, Canninga-van Dijk MR. The glucagonoma syndrome and necrolytic migratory erythema: a clinical review. Eur J Endocrinol. 2004;151:531–7.

    Article  PubMed  Google Scholar 

  23. Nesi G, Marcucci T, Rubio CA, Brandi ML, Tonelli F. Somatostatinoma: clinico-pathological features of three cases and literature reviewed. J Gastroenterol Hepatol. 2008;23:521–6.

    Article  PubMed  CAS  Google Scholar 

  24. Krejs GJ, Orci L, Conlon JM, et al. Somatostatinoma syndrome. Biochemical, morphologic and clinical features. N Engl J Med. 1979;301:285–92.

    Article  PubMed  CAS  Google Scholar 

  25. Verner JV, Morrison AB. Islet cell tumor and a syndrome of refractory watery diarrhea and hypokalemia. Am J Med. 1958;25:374–80.

    Article  PubMed  CAS  Google Scholar 

  26. Lawrence B, Gustafsson BI, Kidd M, Pavel M, Svejda B, Modlin IM. The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am. 2011;40:111–34. viii.

    Article  PubMed  CAS  Google Scholar 

  27. Nobels FR, Kwekkeboom DJ, Coopmans W, et al. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J Clin Endocrinol Metab. 1997;82:2622–8.

    Article  PubMed  CAS  Google Scholar 

  28. Lindholm DP, Oberg K. Biomarkers and molecular imaging in gastroenteropancreatic neuroendocrine tumors. Horm Metab Res. 2011;43:832–7.

    Article  PubMed  CAS  Google Scholar 

  29. Nehar D, Lombard-Bohas C, Olivieri S, et al. Interest of Chromogranin A for diagnosis and follow-up of endocrine tumors. Clin Endocrinol (Oxf). 2004;60:644–52.

    Article  CAS  Google Scholar 

  30. Ahmed A, Turner G, King B, et al. Midgut neuroendocrine tumors with liver metastases: results of the UKINETS study. Endocr Relat Cancer. 2009;16:885–94.

    Article  PubMed  CAS  Google Scholar 

  31. Massironi S, Conte D, Sciola V, et al. Plasma chromogranin A response to octreotide test: prognostic value for clinical outcome in endocrine digestive tumors. Am J Gastroenterol. 2010;105:2072–8.

    Article  PubMed  CAS  Google Scholar 

  32. Kouvaraki MA, Ajani JA, Hoff P, et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol. 2004;22:4762–71.

    Article  PubMed  CAS  Google Scholar 

  33. Yao JC, Lombard-Bohas C, Baudin E, et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol. 2010;28:69–76.

    Article  PubMed  CAS  Google Scholar 

  34. Giusti M, Sidoti M, Augeri C, Rabitti C, Minuto F. Effect of short-term treatment with low dosages of the proton-pump inhibitor omeprazole on serum chromogranin A levels in man. Eur J Endocrinol. 2004;150:299–303.

    Article  PubMed  CAS  Google Scholar 

  35. Binnick AN, Spencer SK, Dennison WL Jr, Horton ES. Glucagonoma syndrome. Report of two cases and literature review. Arch Dermatol. 1977;113:749–54.

    Article  PubMed  CAS  Google Scholar 

  36. Shi W, Liao W, Mei X, Xiao Q, Zeng Y, Zhou Q. Necrolytic migratory erythema associated with glucagonoma syndrome. J Clin Oncol. 2010;28:e329–31.

    Article  PubMed  Google Scholar 

  37. Hayashi D, Tkacz JN, Hammond S, et al. Gastroenteropancreatic neuroendocrine tumors: multimodality imaging features with pathological correlation. Jpn J Radiol. 2011;29:85–91.

    Article  PubMed  Google Scholar 

  38. Sheth S, Hruban RK, Fishman EK. Helical CT of islet cell tumors of the pancreas: typical and atypical manifestations. AJR Am J Roentgenol. 2002;179:725–30.

    PubMed  Google Scholar 

  39. Phan GQ, Yeo CJ, Hruban RH, Lillemoe KD, Pitt HA, Cameron JL. Surgical experience with pancreatic and peripancreatic neuroendocrine tumors: review of 125 patients. J Gastrointest Surg. 1998;2:472–82.

    Article  PubMed  CAS  Google Scholar 

  40. Gouya H, Vignaux O, Augui J, et al. CT, endoscopic sonography, and a combined protocol for preoperative evaluation of pancreatic insulinomas. AJR Am J Roentgenol. 2003;181:987–92.

    PubMed  Google Scholar 

  41. Ichikawa T, Peterson MS, Federle MP, et al. Islet cell tumor of the pancreas: biphasic CT versus MR imaging in tumor detection. Radiology. 2000;216:163–71.

    PubMed  CAS  Google Scholar 

  42. Kraus BB, Ros PR. Insulinoma: diagnosis with fat-suppressed MR imaging. AJR Am J Roentgenol. 1994;162:69–70.

    PubMed  CAS  Google Scholar 

  43. Owen NJ, Sohaib SA, Peppercorn PD, et al. MRI of pancreatic neuroendocrine tumors. Br J Radiol. 2001;74:968–73.

    PubMed  CAS  Google Scholar 

  44. Bakir B, Salmaslioglu A, Poyanli A, Rozanes I, Acunas B. Diffusion weighted MR imaging of pancreatic islet cell tumors. Eur J Radiol. 2010;74:214–20.

    Article  PubMed  Google Scholar 

  45. Herwick S, Miller FH, Keppke AL. MRI of islet cell tumors of the pancreas. AJR Am J Roentgenol. 2006;187:W472–80.

    Article  PubMed  Google Scholar 

  46. Ishikawa T, Itoh A, Kawashima H, et al. Usefulness of EUS combined with contrast-enhancement in the differential diagnosis of malignant versus benign and preoperative localization of pancreatic endocrine tumors. Gastrointest Endosc. 2010;71:951–9.

    Article  PubMed  Google Scholar 

  47. Pais SA, Al-Haddad M, Mohamadnejad M, et al. EUS for pancreatic neuroendocrine tumors: a single-center, 11-year experience. Gastrointest Endosc. 2010;71:1185–93.

    Article  PubMed  Google Scholar 

  48. Figueiredo FA, Giovannini M, Monges G, et al. EUS-FNA predicts 5-year survival in pancreatic endocrine tumors. Gastrointest Endosc. 2009;70:907–14.

    Article  PubMed  Google Scholar 

  49. Atiq M, Bhutani MS, Bektas M, et al. EUS-FNA for pancreatic neuroendocrine tumors: A tertiary cancer center experience. Dig Dis Sci. 2012;57:791–800.

    Article  PubMed  CAS  Google Scholar 

  50. Chatzipantelis P, Salla C, Konstantinou P, Karoumpalis I, Sakellariou S, Doumani I. Endoscopic ultrasound-guided fine-needle aspiration cytology of pancreatic neuroendocrine tumors: a study of 48 cases. Cancer. 2008;114:255–62.

    Article  PubMed  Google Scholar 

  51. Malago R, D'Onofrio M, Zamboni GA, et al. Contrast-enhanced sonography of nonfunctioning pancreatic neuroendocrine tumors. AJR Am J Roentgenol. 2009;192:424–30.

    Article  PubMed  Google Scholar 

  52. Oberg KE, Reubi JC, Kwekkeboom DJ, Krenning EP. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. Gastroenterology. 2010;139:742–53.

    Article  PubMed  CAS  Google Scholar 

  53. Versari A, Camellini L, Carlinfante G, et al. Ga-68 DOTATOC PET, endoscopic ultrasonography, and multidetector CT in the diagnosis of duodenopancreatic neuroendocrine tumors: a single-centre retrospective study. Clin Nucl Med. 2010;35:321–8.

    Article  PubMed  Google Scholar 

  54. Kumar R, Sharma P, Garg P, et al. Role of Ga-DOTATOC PET-CT in the diagnosis and staging of pancreatic neuroendocrine tumors. Eur Radiol. 2011;21:2408–16.

    Article  PubMed  Google Scholar 

  55. Yakemchuk VN, Jager PL, Chirakal R, Reid R, Major P, Gulenchyn KY. PET/CT using 18F-FDOPA provides improved staging of carcinoid tumor patients in a Canadian setting. Nucl Med Commun. 2012;33:322–30.

    Article  PubMed  CAS  Google Scholar 

  56. Bilimoria KY, Talamonti MS, Tomlinson JS, et al. Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: analysis of 3851 patients. Ann Surg. 2008;247:490–500.

    Article  PubMed  Google Scholar 

  57. Chen H, Hardacre JM, Uzar A, Cameron JL, Choti MA. Isolated liver metastases from neuroendocrine tumors: does resection prolong survival? J Am Coll Surg. 1998;187:88–92. discussion −3.

    Article  PubMed  CAS  Google Scholar 

  58. Musunuru S, Chen H, Rajpal S, et al. Metastatic neuroendocrine hepatic tumors: resection improves survival. Arch Surg. 2006;141:1000–4. discussion −5.

    Article  PubMed  Google Scholar 

  59. Nomura N, Fujii T, Kanazumi N, et al. Nonfunctioning neuroendocrine pancreatic tumors: our experience and management. J Hepatobiliary Pancreat Surg. 2009;16:639–47.

    Article  PubMed  Google Scholar 

  60. Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg. 2003;197:29–37.

    Article  PubMed  Google Scholar 

  61. Schurr PG, Strate T, Rese K, et al. Aggressive surgery improves long-term survival in neuroendocrine pancreatic tumors: an institutional experience. Ann Surg. 2007;245:273–81.

    Article  PubMed  Google Scholar 

  62. Touzios JG, Kiely JM, Pitt SC, et al. Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg. 2005;241:776–83. discussion 83–5.

    Article  PubMed  Google Scholar 

  63. Barreto S, Chen J, Padbury R, Wilson T, Maddern G, Kanhere H. Pancreatic neuroendocrine tumors: The South Australian perspective. ANZ J Surg. 2010;80 Suppl 1:A46.

    Google Scholar 

  64. Zerbi A, Capitanio V, Boninsegna L, et al. Surgical treatment of pancreatic endocrine tumors in Italy: results of a prospective multicentre study of 262 cases. Langenbecks Arch Surg. 2011;396:313–21.

    Article  PubMed  Google Scholar 

  65. Hodul PJ, Strosberg JR, Kvols LK. Aggressive surgical resection in the management of pancreatic neuroendocrine tumors: when is it indicated? Cancer Control. 2008;15:314–21.

    PubMed  Google Scholar 

  66. Sarmiento JM, Que FG, Grant CS, Thompson GB, Farnell MB, Nagorney DM. Concurrent resections of pancreatic islet cell cancers with synchronous hepatic metastases: outcomes of an aggressive approach. Surgery. 2002;132:976–82. discussion 82–3.

    Article  PubMed  Google Scholar 

  67. Hackert T, Hinz U, Fritz S, et al. Enucleation in pancreatic surgery: indications, technique, and outcome compared to standard pancreatic resections. Langenbecks Arch Surg. 2011;396:1197–203.

    Article  PubMed  Google Scholar 

  68. Kimura W, Tezuka K, Hirai I. Surgical management of pancreatic neuroendocrine tumors. Surg Today. 2011;41:1332–43.

    Article  PubMed  Google Scholar 

  69. Falconi M, Zerbi A, Crippa S, et al. Parenchyma-preserving resections for small nonfunctioning pancreatic endocrine tumors. Ann Surg Oncol. 2010;17:1621–7.

    Article  PubMed  Google Scholar 

  70. Fernandez-Cruz L, Blanco L, Cosa R, Rendon H. Is laparoscopic resection adequate in patients with neuroendocrine pancreatic tumors? World J Surg. 2008;32:904–17.

    Article  PubMed  Google Scholar 

  71. Falconi M, Bartsch DF, Eriksson B, et al. ENETS Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Neoplasms of the Digestive System: Well-Differentiated Pancreatic Non-Functioning Tumors. Neuroendocrinology. 2012;95:120–34.

    Article  PubMed  CAS  Google Scholar 

  72. Norton JA, Alexander HR, Fraker DL, Venzon DJ, Gibril F, Jensen RT. Comparison of surgical results in patients with advanced and limited disease with multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome. Ann Surg. 2001;234:495–505. discussion −6.

    Article  PubMed  CAS  Google Scholar 

  73. Norton JA, Kivlen M, Li M, Schneider D, Chuter T, Jensen RT. Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors. Arch Surg. 2003;138:859–66.

    Article  PubMed  Google Scholar 

  74. Capurso G, Bettini R, Rinzivillo M, Boninsegna L, Delle Fave G, Falconi M. Role of resection of the primary pancreatic neuroendocrine tumour only in patients with unresectable metastatic liver disease: a systematic review. Neuroendocrinology. 2011;93:223–9.

    Article  PubMed  CAS  Google Scholar 

  75. Bettini R, Mantovani W, Boninsegna L, et al. Primary tumour resection in metastatic nonfunctioning pancreatic endocrine carcinomas. Dig Liver Dis. 2009;41:49–55.

    Article  PubMed  CAS  Google Scholar 

  76. Nguyen SQ, Angel LP, Divino CM, Schluender S, Warner RR. Surgery in malignant pancreatic neuroendocrine tumors. J Surg Oncol. 2007;96:397–403.

    Article  PubMed  Google Scholar 

  77. Solorzano CC, Lee JE, Pisters PW, et al. Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients. Surgery. 2001;130:1078–85.

    Article  PubMed  CAS  Google Scholar 

  78. Steinmuller T, Kianmanesh R, Falconi M, et al. Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2008;87:47–62.

    Article  PubMed  CAS  Google Scholar 

  79. Jagannath P, Chhabra D, Shrikhande S, Shah R. Surgical treatment of liver metastases in neuroendocrine neoplasms. Int J Hepatol. 2012;2012:782672.

    PubMed  Google Scholar 

  80. Basu B, Sirohi B, Corrie P. Systemic therapy for neuroendocrine tumors of gastroenteropancreatic origin. Endocr Relat Cancer. 2010;17:R75–90.

    Article  PubMed  CAS  Google Scholar 

  81. Moertel CG, Hanley JA, Johnson LA. Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med. 1980;303:1189–94.

    Article  PubMed  CAS  Google Scholar 

  82. Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med. 1992;326:519–23.

    Article  PubMed  CAS  Google Scholar 

  83. Fjallskog ML, Janson ET, Falkmer UG, Vatn MH, Oberg KE, Eriksson BK. Treatment with combined streptozotocin and liposomal doxorubicin in metastatic endocrine pancreatic tumors. Neuroendocrinology. 2008;88:53–8.

    Article  PubMed  CAS  Google Scholar 

  84. Ramanathan RK, Cnaan A, Hahn RG, Carbone PP, Haller DG. Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282. Ann Oncol. 2001;12:1139–43.

    Article  PubMed  CAS  Google Scholar 

  85. Bajetta E, Catena L, Procopio G, et al. Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumors? Cancer Chemother Pharmacol. 2007;59:637–42.

    Article  PubMed  CAS  Google Scholar 

  86. Cassier PA, Walter T, Eymard B, et al. Gemcitabine and oxaliplatin combination chemotherapy for metastatic well-differentiated neuroendocrine carcinomas: a single-center experience. Cancer. 2009;115:3392–9.

    Article  PubMed  CAS  Google Scholar 

  87. Kulke MH, Kim H, Clark JW, et al. A Phase II trial of gemcitabine for metastatic neuroendocrine tumors. Cancer. 2004;101:934–9.

    Article  PubMed  CAS  Google Scholar 

  88. Kulke MH, Stuart K, Enzinger PC, et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol. 2006;24:401–6.

    Article  PubMed  CAS  Google Scholar 

  89. Strosberg JR, Fine RL, Choi J, et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer. 2011;117:268–75.

    Article  PubMed  CAS  Google Scholar 

  90. Modlin IM, Pavel M, Kidd M, Gustafsson BI. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumors. Aliment Pharmacol Ther. 2010;31:169–88.

    PubMed  CAS  Google Scholar 

  91. Rinke A, Muller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27:4656–63.

    Article  PubMed  CAS  Google Scholar 

  92. Kvols L, Wiedenmann B, Oberg K, et al. The SOM230 Carcinoid Study Group, 2006. Safety and efficacy of pasireotide (SOM230) in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR: results of a phase II study. J Clin Oncol. 2006;24:198s.

    Google Scholar 

  93. Auernhammer CJ, Goke B. Therapeutic strategies for advanced neuroendocrine carcinomas of jejunum/ileum and pancreatic origin. Gut. 2011;60:1009–21.

    Article  PubMed  CAS  Google Scholar 

  94. Harring TR, Nguyen NT, Goss JA, O'Mahony CA. Treatment of liver metastases in patients with neuroendocrine tumors: a comprehensive review. Int J Hepatol. 2011;2011:154541.

    PubMed  Google Scholar 

  95. Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26:2124–30.

    Article  PubMed  CAS  Google Scholar 

  96. Kwekkeboom D, Herder W, Kam B, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26:2124–30.

    Article  PubMed  CAS  Google Scholar 

  97. Kwekkeboom D, Teunissen J, Bakker W, et al. Radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol. 2005;23:2754–62.

    Article  PubMed  CAS  Google Scholar 

  98. Kam B, Teunissen J, Krenning E, et al. Lutetium-labelled peptides for therapy of neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2012;39 Suppl 1:S103–12.

    Article  PubMed  CAS  Google Scholar 

  99. Dubey N, Varshney R, Shukla J, et al. Synthesis and evaluation of biodegradable PCL/PEG nanoparticles for neuroendocrine tumor targeted delivery of somatostatin analog. Drug Deliv. 2012;19:132–42.

    Article  PubMed  CAS  Google Scholar 

  100. Hanson MW, Feldman JM, Blinder RA, Moore JO, Coleman RE. Carcinoid tumors: iodine-131 MIBG scintigraphy. Radiology. 1989;172:699–703.

    PubMed  CAS  Google Scholar 

  101. Chastain MA. The glucagonoma syndrome: a review of its features and discussion of new perspectives. Am J Med Sci. 2001;321:306–20.

    Article  PubMed  CAS  Google Scholar 

  102. Zollinger RM, Ellison EH. Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas. Ann Surg. 1955;142:709–23. discussion 24–8.

    Article  PubMed  CAS  Google Scholar 

  103. Metz DC. Diagnosis of the Zollinger-Ellison Syndrome. Clin Gastroenterol Hepatol. 2012;10:126–30.

    Article  PubMed  Google Scholar 

  104. Gibril F, Reynolds JC, Chen CC, et al. Specificity of somatostatin receptor scintigraphy: a prospective study and effects of false-positive localizations on management in patients with gastrinomas. J Nucl Med. 1999;40:539–53.

    PubMed  CAS  Google Scholar 

  105. Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology. 2008;135:1469–92.

    Article  PubMed  CAS  Google Scholar 

  106. Wilcox CM, Seay T, Arcury JT, Mohnen J, Hirschowitz BI. Zollinger-Ellison syndrome: presentation, response to therapy, and outcome. Dig Liver Dis. 2011;43:439–43.

    Article  PubMed  Google Scholar 

  107. Whipple A. The surgical therapy of hyperinsulinism. J Int Chir. 1938;3:237–76.

    Google Scholar 

  108. Whipple A, Franz V. Adenoma of islet cells with hyperinsulinism. Am Surg. 1935;101:1299–335.

    CAS  Google Scholar 

  109. Stefanini P, Carboni M, Patrassi N, Basoli A. Beta-islet cell tumors of the pancreas: results of a study on 1,067 cases. Surgery. 1974;75:597–609.

    PubMed  CAS  Google Scholar 

  110. Grama D, Eriksson B, Martensson H, et al. Clinical characteristics, treatment and survival in patients with pancreatic tumors causing hormonal syndromes. World J Surg. 1992;16:632–9.

    Article  PubMed  CAS  Google Scholar 

  111. Fidler JL, Fletcher JG, Reading CC, et al. Preoperative detection of pancreatic insulinomas on multiphasic helical CT. AJR Am J Roentgenol. 2003;181:775–80.

    PubMed  CAS  Google Scholar 

  112. Varma V, Tariciotti L, Coldham C, Taniere P, Buckels JA, Bramhall SR. Preoperative localisation and surgical management of insulinoma: single centre experience. Dig Surg. 2011;28:63–73.

    Article  PubMed  Google Scholar 

  113. Liu Y, Song Q, Jin HT, Lin XZ, Chen KM. The value of multidetector-row CT in the preoperative detection of pancreatic insulinomas. Radiol Med. 2009;114:1232–8.

    Article  PubMed  CAS  Google Scholar 

  114. Vaidakis D, Karoubalis J, Pappa T, Piaditis G, Zografos GN. Pancreatic insulinoma: current issues and trends. Hepatobiliary Pancreat Dis Int. 2010;9:234–41.

    PubMed  Google Scholar 

  115. Angeli E, Vanzulli A, Castrucci M, et al. Value of abdominal sonography and MR imaging at 0.5 T in preoperative detection of pancreatic insulinoma: a comparison with dynamic CT and angiography. Abdom Imaging. 1997;22:295–303.

    Article  PubMed  CAS  Google Scholar 

  116. Semelka RC, Cumming MJ, Shoenut JP, et al. Islet cell tumors: comparison of dynamic contrast-enhanced CT and MR imaging with dynamic gadolinium enhancement and fat suppression. Radiology. 1993;186:799–802.

    PubMed  CAS  Google Scholar 

  117. Druce MR, Muthuppalaniappan VM, O'Leary B, et al. Diagnosis and localisation of insulinoma: the value of modern magnetic resonance imaging in conjunction with calcium stimulation catheterisation. Eur J Endocrinol. 2010;162:971–8.

    Article  PubMed  CAS  Google Scholar 

  118. Sotoudehmanesh R, Hedayat A, Shirazian N, et al. Endoscopic ultrasonography (EUS) in the localization of insulinoma. Endocrine. 2007;31:238–41.

    Article  PubMed  CAS  Google Scholar 

  119. Guettier JM, Kam A, Chang R, et al. Localization of insulinomas to regions of the pancreas by intraarterial calcium stimulation: the NIH experience. J Clin Endocrinol Metab. 2009;94:1074–80.

    Article  PubMed  CAS  Google Scholar 

  120. Morganstein DL, Lewis DH, Jackson J, et al. The role of arterial stimulation and simultaneous venous sampling in addition to cross-sectional imaging for localisation of biochemically proven insulinoma. Eur Radiol. 2009;19:2467–73.

    Article  PubMed  CAS  Google Scholar 

  121. Cohen M, Bower R, Fidler S, Johnsonbaugh R, Sode J. Inhibition of insulin release by diphenylhydantoin and diazoxide in a patient with benign insulinoma. Lancet. 1973;1:40–1.

    Article  PubMed  CAS  Google Scholar 

  122. Wd H, Niederle B, Scoazec J, et al. Well-differentiated pancreatic tumor/carcinoma: insulinoma. Neuroendocrinology. 2006;84:183–8.

    Article  CAS  Google Scholar 

  123. Tucker ON, Crotty PL, Conlon KC. The management of insulinoma. Br J Surg. 2006;93:264–75.

    Article  PubMed  CAS  Google Scholar 

  124. Lo CY, Lo CM, Fan ST. Role of laparoscopic ultrasonography in intraoperative localization of pancreatic insulinoma. Surg Endosc. 2000;14:1131–5.

    Article  PubMed  CAS  Google Scholar 

  125. Mabrut JY, Fernandez-Cruz L, Azagra JS, et al. Laparoscopic pancreatic resection: results of a multicenter European study of 127 patients. Surgery. 2005;137:597–605.

    Article  PubMed  Google Scholar 

  126. Zhao YP, Zhan HX, Zhang TP, et al. Surgical management of patients with insulinomas: Result of 292 cases in a single institution. J Surg Oncol. 2011;103:169–74.

    Article  PubMed  Google Scholar 

  127. Liu H, Peng C, Zhang S, et al. Strategy for the surgical management of insulinomas: analysis of 52 cases. Dig Surg. 2007;24:463–70.

    Article  PubMed  CAS  Google Scholar 

  128. Kress O, Wagner HJ, Wied M, Klose KJ, Arnold R, Alfke H. Transarterial chemoembolization of advanced liver metastases of neuroendocrine tumors–a retrospective single-center analysis. Digestion. 2003;68:94–101.

    Article  PubMed  CAS  Google Scholar 

  129. Vogl TJ, Naguib NN, Zangos S, Eichler K, Hedayati A, Nour-Eldin NE. Liver metastases of neuroendocrine carcinomas: interventional treatment via transarterial embolization, chemoembolization and thermal ablation. Eur J Radiol. 2009;72:517–28.

    Article  PubMed  Google Scholar 

  130. Gupta S, Johnson MM, Murthy R, et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer. 2005;104:1590–602.

    Article  PubMed  Google Scholar 

  131. Kvols LK, Turaga KK, Strosberg J, Choi J. Role of interventional radiology in the treatment of patients with neuroendocrine metastases in the liver. J Natl Compr Canc Netw. 2009;7:765–72.

    PubMed  Google Scholar 

  132. Madoff DC, Gupta S, Ahrar K, Murthy R, Yao JC. Update on the management of neuroendocrine hepatic metastases. J Vasc Interv Radiol. 2006;17:1235–49. quiz– 50.

    Article  PubMed  Google Scholar 

  133. Nazario J, Gupta S. Transarterial liver-directed therapies of neuroendocrine hepatic metastases. Semin Oncol. 2010;37:118–26.

    Article  PubMed  Google Scholar 

  134. Marrache F, Vullierme MP, Roy C, et al. Arterial phase enhancement and body mass index are predictors of response to chemoembolisation for liver metastases of endocrine tumors. Br J Cancer. 2007;96:49–55.

    Article  PubMed  CAS  Google Scholar 

  135. Akyildiz HY, Mitchell J, Milas M, Siperstein A, Berber E. Laparoscopic radiofrequency thermal ablation of neuroendocrine hepatic metastases: long-term follow-up. Surgery. 2010;148:1288–93. discussion–93.

    Article  PubMed  Google Scholar 

  136. Berber E, Flesher N, Siperstein AE. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases. World J Surg. 2002;26:985–90.

    Article  PubMed  Google Scholar 

  137. Berber E, Siperstein A. Laparoscopic radiofrequency thermal ablation of adrenal tumors: technical details. Surg Laparosc Endosc Percutan Tech. 2010;20:58–62.

    Article  PubMed  Google Scholar 

  138. Berber E, Tsinberg M, Tellioglu G, Simpfendorfer CH, Siperstein AE. Resection versus laparoscopic radiofrequency thermal ablation of solitary colorectal liver metastasis. J Gastrointest Surg. 2008;12:1967–72.

    Article  PubMed  Google Scholar 

  139. Mazzaglia PJ, Berber E, Milas M, Siperstein AE. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival. Surgery. 2007;142:10–9.

    Article  PubMed  Google Scholar 

  140. Strosberg JR, Cheema A, Kvols LK. A review of systemic and liver-directed therapies for metastatic neuroendocrine tumors of the gastroenteropancreatic tract. Cancer Control. 2011;18:127–37.

    PubMed  Google Scholar 

  141. Kalinowski M, Dressler M, Konig A, et al. Selective internal radiotherapy with Yttrium-90 microspheres for hepatic metastatic neuroendocrine tumors: a prospective single center study. Digestion. 2009;79:137–42.

    Article  PubMed  Google Scholar 

  142. Cao CQ, Yan TD, Bester L, Liauw W, Morris DL. Radioembolization with yttrium microspheres for neuroendocrine tumour liver metastases. Br J Surg. 2010;97:537–43.

    Article  PubMed  CAS  Google Scholar 

  143. Kennedy AS, Dezarn WA, McNeillie P, et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol. 2008;31:271–9.

    Article  PubMed  Google Scholar 

  144. Rhee TK, Lewandowski RJ, Liu DM, et al. 90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience. Ann Surg. 2008;247:1029–35.

    Article  PubMed  Google Scholar 

  145. King J, Quinn R, Glenn DM, et al. Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer. 2008;113:921–9.

    Article  PubMed  Google Scholar 

  146. Murthy R, Eng C, Krishnan S, et al. Hepatic yttrium-90 radioembolotherapy in metastatic colorectal cancer treated with cetuximab or bevacizumab. J Vasc Interv Radiol. 2007;18:1588–91.

    Article  PubMed  Google Scholar 

  147. Crowder CD, Grabowski C, Inampudi S, Sielaff T, Sherman CA, Batts KP. Selective internal radiation therapy-induced extrahepatic injury: an emerging cause of iatrogenic organ damage. Am J Surg Pathol. 2009;33:963–75.

    Article  PubMed  Google Scholar 

  148. Konda A, Savin MA, Cappell MS, Duffy MC. Radiation microsphere-induced GI ulcers after selective internal radiation therapy for hepatic tumors: an underrecognized clinical entity. Gastrointest Endosc. 2009;70:561–7.

    Article  PubMed  Google Scholar 

  149. Mascarenhas NB, Mulcahy MF, Lewandowski RJ, Salem R, Ryu RK. Hepatic abscess after yttrium-90 radioembolization for islet-cell tumor hepatic metastasis. Cardiovasc Intervent Radiol. 2010;33:650–3.

    Article  PubMed  Google Scholar 

  150. Kennedy AS, McNeillie P, Dezarn WA, et al. Treatment parameters and outcome in 680 treatments of internal radiation with resin 90Y-microspheres for unresectable hepatic tumors. Int J Radiat Oncol Biol Phys. 2009;74:1494–500.

    Article  PubMed  CAS  Google Scholar 

  151. Murthy R, Kamat P, Nunez R, et al. Yttrium-90 microsphere radioembolotherapy of hepatic metastatic neuroendocrine carcinomas after hepatic arterial embolization. J Vasc Interv Radiol. 2008;19:145–51.

    Article  PubMed  Google Scholar 

  152. Saxena A, Chua TC, Bester L, Kokandi A, Morris DL. Factors predicting response and survival after yttrium-90 radioembolization of unresectable neuroendocrine tumor liver metastases: a critical appraisal of 48 cases. Ann Surg. 2010;251:910–6.

    Article  PubMed  Google Scholar 

  153. Detjen KM, Welzel M, Farwig K, et al. Molecular mechanism of interferon alfa-mediated growth inhibition in human neuroendocrine tumor cells. Gastroenterology. 2000;118:735–48.

    Article  PubMed  CAS  Google Scholar 

  154. Hofland LJ, de Herder WW, Waaijers M, et al. Interferon-alpha-2a is a potent inhibitor of hormone secretion by cultured human pituitary adenomas. J Clin Endocrinol Metab. 1999;84:3336–43.

    Article  PubMed  CAS  Google Scholar 

  155. Eriksson B, Kloppel G, Krenning E, et al. Consensus guidelines for the management of patients with digestive neuroendocrine tumors–well-differentiated jejunal-ileal tumor/carcinoma. Neuroendocrinology. 2008;87:8–19.

    Article  PubMed  CAS  Google Scholar 

  156. Boudreaux JP, Klimstra DS, Hassan MM, et al. The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and Cecum. Pancreas. 2010;39:753–66.

    Article  PubMed  Google Scholar 

  157. Plockinger U, Wiedenmann B. Neuroendocrine tumors. Biotherapy. Best Pract Res Clin Endocrinol Metab. 2007;21:145–62.

    Article  PubMed  CAS  Google Scholar 

  158. Verhoef S, van Diemen-Steenvoorde R, Akkersdijk WL, et al. Malignant pancreatic tumour within the spectrum of tuberous sclerosis complex in childhood. Eur J Pediatr. 1999;158:284–7.

    Article  PubMed  CAS  Google Scholar 

  159. Vignot S, Faivre S, Aguirre D, Raymond E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol. 2005;16:525–37.

    Article  PubMed  CAS  Google Scholar 

  160. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:514–23.

    Article  PubMed  CAS  Google Scholar 

  161. Pavel M, Hainsworth J, Baudin E, et al. A randomized, double-blind, placebo-controlled, multicenter phase III trial of everolimus+octreotide LAR vs placebo+octreotide lAR in patients with advanced neuroendocrine tumors (NET) (RADIANT-2). Ann Oncol. 2010;21 suppl 8:viii4.

    Google Scholar 

  162. Yao JC, Phan A, Hoff PM, et al. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol. 2008;26:1316–23.

    Article  PubMed  CAS  Google Scholar 

  163. Kulke MH, Lenz HJ, Meropol NJ, et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol. 2008;26:3403–10.

    Article  PubMed  CAS  Google Scholar 

  164. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:501–13.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Gastrointestinal and Hepato-Pancreato-Biliary Surgical Oncology, Tata Memorial Centre, Ernest Borges Marg, Parel, Mumbai, 400 012, India

    Shailesh V. Shrikhande, Mahesh Goel & Savio G. Barreto

  2. Medical and Hemato-Oncology, Artemis Health Sciences, Sector 51, Gurgaon, 122 001, India

    Bhawna Sirohi

Authors
  1. Shailesh V. Shrikhande
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bhawna Sirohi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mahesh Goel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Savio G. Barreto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shailesh V. Shrikhande.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shrikhande, S.V., Sirohi, B., Goel, M. et al. Pancreatic neuroendocrine tumors. Indian J Gastroenterol 32, 3–17 (2013). https://doi.org/10.1007/s12664-012-0257-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12664-012-0257-2

Keywords

Search

Navigation